SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics (Pinksheets: VRAL) today published its March 2012 Letter to Shareholders. Providing updates on the company’s progress, the letter discusses the recent Pre-IND filing for its Lyme Disease drug candidate, notes other drugs in the pipeline that have developed out of the company’s Metabolic Disruption Technology Platform, and talks about progress in proving the efficacy of the yield enhancement in the company’s algal biofuels subsidiary, VG Energy.
